Clinical Trial

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The study is to evaluate the efficacy of KL-A167 combined with cisplatin and gemcitabine vs placebo combined with cisplatin and gemcitabine in the treatment of recurrent or metastatic nasopharyngeal carcinoma, as measured by progression-free survival (PFS) per the Response Evaluation Criteria in Solid Tumors RECIST Version 1.1
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-03-15; most recent amendment 2026-05-05.
Status change: Not Yet Recruiting → Active, Not Recruiting 2023-10-19
Trial Details
NCT Number NCT05294172
Lead Sponsor Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Conditions Nasopharyngeal Carcinoma, Recurrent or Metastatic
Enrollment 295 participants
Start Date 2022-06-07
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-08